Your browser doesn't support javascript.
loading
The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.
Fitzal, F; Filipits, M; Rudas, M; Greil, R; Dietze, O; Samonigg, H; Lax, S; Herz, W; Dubsky, P; Bartsch, R; Kronenwett, R; Gnant, M.
Afiliação
  • Fitzal F; 1] Hospital of the Sisters of Charity, Breast Health Center, Linz, Austria [2] Department of Surgery and Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria.
  • Filipits M; Department of Oncology, Medical University Vienna, Vienna, Austria.
  • Rudas M; Department of Pathology, Medical University Vienna, Vienna, Austria.
  • Greil R; Department of Oncology, Salzburger Landesklinik, Salzburg, Austria.
  • Dietze O; Department of Pathology, Salzburger Landesklinik, Salzburg, Austria.
  • Samonigg H; Department of Oncology, Medical University Graz, Graz, Austria.
  • Lax S; Department of Pathology, Medical University Graz, Graz, Austria.
  • Herz W; Department of Surgery, KH Leoben, Leoben, Austria.
  • Dubsky P; Department of Surgery and Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria.
  • Bartsch R; Department of Oncology, Medical University Vienna, Vienna, Austria.
  • Kronenwett R; Sividon Diagnostics, Cologne, Germany.
  • Gnant M; Department of Surgery and Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria.
Br J Cancer ; 112(8): 1405-10, 2015 Apr 14.
Article em En | MEDLINE | ID: mdl-25867274
BACKGROUND: The aim of this study was to examine whether EndoPredict (EP), a novel genomic expression test, is effective in predicting local recurrence (LR)-free survival (LRFS) following surgery for breast cancer in postmenopausal women. In addition, we examined whether EP may help tailor local therapy in these patients. METHODS: From January 1996 to June 2004, 3714 postmenopausal patients were randomly assigned to either tamoxifen or tamoxifen followed by anastrozole within the prospective ABCSG 8 trial. Using assay scores from EP, we classified breast tumour blocks as either low or high risk for recurrence. RESULTS: Data were gathered from 1324 patients. The median follow-up was 72.3 months and the cumulative incidence of LR was 2.6% (0.4% per year). The risk of LR over a 10-year period among patients with high-risk lesions (n=683) was significantly higher (LRFS=91%) when compared with patients with low-risk lesions (n=641) (10-year LRFS=97.5%) (HR: 1.31 (1.16-1.48) P<0.005). The groups that received breast conservation surgery (BCT) and mastectomy (MX) had similar LR rates (P=0.879). Radiotherapy (RT) after BCT significantly improved LRFS in the cohorts predicted by EP to be low-risk for LR (received RT: n=436, 10-year LRFS 99.8%; did not receive RT: n=63, 10-year LRFS 83.6%, P<0.005). CONCLUSIONS: EndoPredict is an effective prognostic tool for predicting LRFS. Among postmenopausal, low-risk patients, EP does not appear to be useful for tailoring local therapy.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Kit de Reagentes para Diagnóstico / Neoplasias da Mama / RNA Neoplásico / Receptores de Estrogênio / Receptor ErbB-2 / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Kit de Reagentes para Diagnóstico / Neoplasias da Mama / RNA Neoplásico / Receptores de Estrogênio / Receptor ErbB-2 / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article